Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $112 to $94.
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.